139911-30-1

Basic information

• Product Name: Ethyl 2-chloro-5-fluoronicotinate
• Synonyms: 2-CHLORO-5-FLUORONICOTINIC ACID ETHYL ESTER;Ethyl2-Chloro-5-fluoronicotinicacid;2-CHLORO-5-FLUORONICOTONIC ACID ETHYL ESTER;Ethyl 2-chloro-5-fluoronicotinate;2-CHLORO-5-FLUORONICOTINI...;ethyl 2-chloro-5-fluoropyridine-3-carboxylate;Ethyl 2-chloro-5-fluoropyridine-3-carboxylate, 2-Chloro-3-(ethoxycarbonyl)-5-fluoropyridine;ethyl 2-chloro-5-fluoropyridin-3-carboxylate
• CAS NO: 139911-30-1
• Molecular Formula: C₈H₇ClFNO₂
• Molecular Weight: 203.6
• Product Categories: Pyridine;pharmacetical;Pyridines
• Mol File: 139911-30-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 252.654 °C at 760 mmHg
• Flash Point: 106.602 °C
• Appearance: /
• Density: 1.329 g/cm³
• Vapor Pressure: 0.0191mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Ethyl 2-chloro-5-fluoronicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-chloro-5-fluoronicotinate(139911-30-1)
• EPA Substance Registry System: Ethyl 2-chloro-5-fluoronicotinate(139911-30-1)

Safety Data

• Hazardous Substances Data: 139911-30-1(Hazardous Substances Data)

Usage

General Description

Ethyl 2-chloro-5-fluoronicotinate is a chemical compound with the molecular formula C8H6ClFNO2. It is a derivative of nicotinic acid and is used as an intermediate in the synthesis of pharmaceutical compounds. Ethyl 2-chloro-5-fluoronicotinate is a white to off-white solid and is soluble in organic solvents. Ethyl 2-chloro-5-fluoronicotinate is primarily used in the pharmaceutical industry for the production of drugs with potential therapeutic benefits. It is important to handle this chemical with caution, as it may pose health hazards if not used properly. Overall, this compound plays a crucial role in the development of various pharmaceutical products.

InChI:InChI=1/C8H7ClFNO2/c1-2-13-8(12)6-3-5(10)4-11-7(6)9/h3-4H,2H2,1H3

Upstream product

• 82671-06-5 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid 
• 64-17-5 ethanol 
• 1316084-72-6 (2E,4Z)-ethyl 2-cyano-5-(dimethylamino)-4-fluoro-penta-2,4-dienoate 
• 38186-88-8 2-chloro-5-fluoronicotinic acid 
• 82671-03-2 ethyl 2,6-dichloro-5-fluoropyridine-3-carboxylate 
• 151322-65-5 ethyl 2-chloro-5-fluoro-6-(methylthio)pyridine-3-carboxylate 

Downstream Products

• 582333-25-3 2-(3,4-dichloro-phenoxy)-5-fluoro-nicotinic acid ethyl ester 
• 1316084-69-1 C₁₄H₁₀F₃NO₃ 
• 791644-48-9 2-chloro-5-fluoronicotinonitrile 
• 884494-33-1 2-chloro-5-fluoro-3-iodo-pyridine 
• 1239355-71-5 C₁₂H₆Cl₂FNO₃ 
• 1239355-72-6 C₁₂H₇ClFNO₃ 
• 1239354-65-4 2-[(2,4-dichlorophenyl)oxy]-5-fluoro-N-[(1R)-2-(4-methylpiperazin-1-yl)-2-oxo-1-{[(phenylmethyl)oxy]methyl}ethyl]pyridine-3-carboxamide 
• 1239354-63-2 2-[(4-chlorophenyl)oxy]-5-fluoro-N-[(1R)-2-(4-methylpiperazin-1-yl)-2-oxo-1-{[(phenylmethyl)oxy]methyl}ethyl]pyridine-3-carboxamide 
• 948915-40-0 Ethyl 2-({[4-(1,1-dimethylethyl)phenyl]methyl}amino)-5-fluoro-3-pyridinecarboxylate 
• 139911-21-0 ethyl 2-(2-methyl-4-fluorophenyl)-5-fluoro-3-pyridinecarboxylate 
• 582333-27-5 2-(3,5-Difluoro-phenoxy)-5-fluoro-nicotinic Acid Ethyl Ester 
• 837377-30-7 5-fluoro-2-(3-ethylsulfanyl-phenoxy)-nicotinic acid ethyl ester 
• 837377-33-0 5-fluoro-2-(4-methylsulfanyl-phenoxy)-nicotinic acid ethyl ester 
• 832099-54-4 5-fluoro-2-(3-methylsulphanyl-phenoxy)-nicotinic acid ethyl ester 

Relevant articles and documents

A modified approach to C-14-labeled 2-(3,4-difluorophenoxy)-5- fluoronicotinic acid and other halogen-substituted analogs

A modified approach to a carbon-14-labeled pyridine ring system was developed based on the electrocyclic ring-closure of 1,4,4-trisubstituted butadiene. The new method was applied to prepare 2-(3,4-difluorophenoxy)-5- fluoro-[2-14C] nicotinic a

Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt

To provide a method for producing a 3-substituted 2-chloro-5-fluoro-pyridine or its salt in high yield from a readily available material through a short process under mild reaction conditions using a reagent which is easy for handling and simple in the reaction operation. Namely, a method for producing the following compound (2) or its salt which comprises selectively reducing a chlorine atom at the 6-position of the following compound (1) or its salt, is provided. Further, a method for producing the following compound (4) or its salt which comprises substituting a Z1 group of the following compound (2) or its salt obtained by the reduction reaction, by a Z2 group, is provided. Here, Z1 is —CO2R1, etc., and R1 is a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, an aralkyl group or a cycloalkyl group. Z2 is a group different from Z1 and is —CO2R5, etc., and R5 is an alkyl group, an alkenyl group, an aryl group, an aralkyl group or a cycloalkyl group.

Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2;n is 1 or 2; A is is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6)alkyl, -(C2-C6)alkenyl, or -(C2-C6)alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is ―O―; ―S(=O)t―, where t is 0, 1, or 2; or -N(R3)―; Y is C(R1a)―, or -[N□(O)k] where k is 0 or 1; R4, R5 and R6 are (1)―H; provided that R5 and R6 are not both -H at the same time, ―F; ―Cl; -(C2-C4) alkynyl; -R16; ―OR16; -S(=O)pR16; ―C(=O)R16, -C(=O)OR16; -OC(=O)R16; -CN; -NO2; -C(=O)NR16R17; -OC(=O)NR16R17; ―NR12aC(=O)NR16R17; -NR12aC(=NR12)NR16R17; -NR12aC(=NCN)NR15R16; -NR12aC(=N-NO2)NR15R16; -C(=NR12a)NR15R16; -CH2C(=NR12a)NR16R17; ―OC(=NR12a)NR16R17; ―OC(=N―NO2)NR16R17; -NR16R17; -CH2NR16R17; -NR12aC(=O)R16; -NR12aC(=O)OR16; =NOR16; ―NR12aS(=O)pR17 -S(=O)pNR16R17; and ―CH2C(=NR12a)NR16R17;(2) -(C1-C4) alkyl including dimethyl and -(C1-C4) alkoxy substituted with 0 to 3 substituents ―F or ―Cl; or 0 or 1 substituent (C1-C2) alkoxycarbonyl―, (C1-C2) alkylcarbonyl―, or (C1-C2) alkylcarbonyloxy―; or (3) an aryl or heterocyclic moiety; or (4) R5 and R6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15):B1 and B2 is a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic; wherein optionally one carbon atom thereof may be replaced by a heteroatom selected from N, O and S; and where N is selected, optionally a second carbon atom thereof may be replaced by a heteroatom selected from N, O, or S; or a pharmaceutically acceptable salt thereof.